{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:51:20Z","timestamp":1790369480016,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100301","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:42:10Z","timestamp":1784043730000},"page":"100301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Orforglipron for obesity treatment in older patients \u226565\u202fyears with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-9609","authenticated-orcid":false,"given":"Deborah B.","family":"Horn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpana P.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1093-2508","authenticated-orcid":false,"given":"Elvis","family":"Twum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl Elaine","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja Giljanovic","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.obpill.2026.100301_bib1","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.obpill.2026.100301_bib3","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"S2","key":"10.1016\/j.obpill.2026.100301_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.16263","article-title":"An overview of obesity-related complications: the epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes","volume":"27","author":"Bl\u00fcher","year":"2025","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100301_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","article-title":"Obesity pharmacotherapy in older adults: a narrative review of evidence","volume":"49","author":"Henney","year":"2025","journal-title":"Int J Obes"},{"issue":"1","key":"10.1016\/j.obpill.2026.100301_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare","year":"2024","journal-title":"Glob Heart"},{"issue":"12","key":"10.1016\/j.obpill.2026.100301_bib7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jama.2024.15563","article-title":"Leading causes of death in the US, 2019-2023","volume":"332","author":"Ahmad","year":"2024","journal-title":"JAMA"},{"issue":"S1","key":"10.1016\/j.obpill.2026.100301_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.24267","article-title":"A geriatrician's approach to managing the complex older adult with obesity","volume":"33","author":"Dewar","year":"2025","journal-title":"Obesity"},{"issue":"9","key":"10.1016\/j.obpill.2026.100301_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.obpill.2026.100301_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA Clinical Practice Guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.obpill.2026.100301_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7570\/jomes21022","article-title":"2020 Korean Society for the Study of Obesity Guidelines for the management of obesity in Korea","volume":"30","author":"Kim","year":"2021","journal-title":"J Obes Metab Syndr"},{"issue":"10278","key":"10.1016\/j.obpill.2026.100301_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.obpill.2026.100301_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"10402","key":"10.1016\/j.obpill.2026.100301_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"9-a Suppl","key":"10.1016\/j.obpill.2026.100301_bib15","first-page":"S30","article-title":"Health-related quality of life assessments with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus","volume":"24","author":"Billings","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.obpill.2026.100301_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02813432.2025.2477141","article-title":"Patients' experiences with GLP1-RAs - a systematic review","volume":"43","author":"Ibsen","year":"2025","journal-title":"Scand J Prim Health Care"},{"issue":"7","key":"10.1016\/j.obpill.2026.100301_bib17","article-title":"The expanding benefits of GLP-1 medicines","volume":"6","author":"Gonzalez-Rellan","year":"2025","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.obpill.2026.100301_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists\u2014effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.obpill.2026.100301_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10557-023-07488-3","article-title":"US population eligibility and estimated impact of semaglutide treatment on obesity prevalence and cardiovascular disease events","volume":"39","author":"Wong","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.obpill.2026.100301_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/oby.70098","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists use in elderly people with obesity\u2014A meta-analysis","author":"Rego de Figueiredo","year":"2026","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2026.100301_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2025.105981","article-title":"Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials","volume":"138","author":"Waqas","year":"2025","journal-title":"Arch Gerontol Geriatr"},{"issue":"9","key":"10.1016\/j.obpill.2026.100301_bib22","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1111\/dom.13331","article-title":"Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials","volume":"20","author":"Warren","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"24","key":"10.1016\/j.obpill.2026.100301_bib23","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100301_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.686990","article-title":"High prevalence of multimorbidity and polypharmacy in elderly patients with chronic pain receiving home care are associated with multiple medication-related problems","volume":"12","author":"Schneider","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.obpill.2026.100301_bib25","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1016\/S2666-7568(24)00007-2","article-title":"Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review","volume":"5","author":"Nicholson","year":"2024","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.obpill.2026.100301_bib26","series-title":"Plainsboro, NJ","article-title":"Wegovy (semaglutide) [package insert]","year":"2025"},{"key":"10.1016\/j.obpill.2026.100301_bib27","author":"Nordisk"},{"issue":"9","key":"10.1016\/j.obpill.2026.100301_bib28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamainternmed.2024.2781","article-title":"Prescription medication use among older adults in the US","volume":"184","author":"Innes","year":"2024","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.obpill.2026.100301_bib30","series-title":"Foundayo (orforglipron)","year":"2026"},{"issue":"18","key":"10.1016\/j.obpill.2026.100301_bib31","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"issue":"10522","key":"10.1016\/j.obpill.2026.100301_bib32","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/S0140-6736(25)02165-8","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial","volume":"406","author":"Horn","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.obpill.2026.100301_bib33","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1111\/dom.70783","article-title":"Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight","volume":"28","author":"Ma","year":"2026","journal-title":"Diabetes Obes Metabol"},{"issue":"3","key":"10.1016\/j.obpill.2026.100301_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12310","article-title":"Validation of a new measure of quality of life in obesity trials: impact of weight on quality of Life-Lite Clinical Trials Version","volume":"9","author":"Kolotkin","year":"2019","journal-title":"Clin Obes"},{"key":"10.1016\/j.obpill.2026.100301_bib35","series-title":"User's manual for the SF36v2 Health Survey","year":"2011"},{"key":"10.1016\/j.obpill.2026.100301_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.675523","article-title":"Health-related quality of life in patients with different diseases measured with the EQ-5D-5L: a systematic review","volume":"9","author":"Zhou","year":"2021","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.obpill.2026.100301_bib37","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.16174","article-title":"Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly)","volume":"27","author":"Fiore","year":"2025","journal-title":"Diabetes Obes Metabol"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:33:33Z","timestamp":1787988813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"alternative-id":["S2667368126000574"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100301","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Orforglipron for obesity treatment in older patients \u226565\u202fyears with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100301"}}